Sp108
REDUCING READMISSIONS FOR GI BLEEDING
Date
May 6, 2023
Explore related products in the following collection:
Society: AGA
This session is designed to demonstrate successful quality improvement in practices and across institutions with the focus on and meaningful real world implementation across a range of GI conditions. This session will discuss how to translate clinical research into quality improvement initiatives leading to successful improvement in patient outcomes. Attendees will also be able to incorporate feedback to improve patient satisfaction as well as reimbursement strategies as well as improving healthcare for socially disadvantaged populations and women's health.
This session is designed to demonstrate successful quality improvement in practices and across institutions with the focus on and meaningful real world implementation across a range of GI conditions. This session will discuss how to translate clinical research into quality improvement initiatives leading to successful improvement in patient outcomes. Attendees will also be able to incorporate feedback to improve patient satisfaction as well as reimbursement strategies as well as improving healthcare for socially disadvantaged populations and women's health.
Presenter
University of Pennsylvania
Tracks
Related Products
PLACEHOLDER
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
EFFECTIVE ADVOCACY ACROSS PARTY LINES: WHAT TO DO WHEN YOU DON'T LIKE YOUR MEMBER OF CONGRESS
This session will provide attendees with an overview of physician advocacy, how it impacts the GI community and how to get involved…
MONITORING OF CALPROTECTIN IN INFLAMMATORY BOWEL DISEASE USING A SWEAT BASED WEARABLE DEVICE
Switching from originator to biosimilar infliximab (IFX) is effective and safe. However, data on multiple switching are scarce. The Edinburgh IBD unit has undertaken three switch programmes: (1) Remicade to CT-P13 (2016), (2) CT-P13 to SB2 (2020), and (3) SB2 to CT-P13 (2021)…
INTRODUCTION
SOCIETY: AGA
